D
Actinium Pharmaceuticals, Inc. ATNM
$1.39 -$0.13-8.55%
Recommendation
Sell
Prev Close
$1.52
Volume
291,751
Avg Vol (90D)
511,244
Market Cap
$47.42M
Dividend & Yield
--
52-Week Range
$1.03 - $10.24
P/E (TTM)
--
EPS (TTM)
-$1.27
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
4/3/2025 - Globe Newswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
4/2/2025 - Business Wire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
4/2/2025 - Globe Newswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
4/1/2025 - PR Newswire
ACTINIUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
4/1/2025 - Globe Newswire
Actinium Pharmaceuticals, Inc. Shareholder Notice: Robbins LLP Reminds Investors of the Class Action Against ATNM
3/31/2025 - Globe Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
3/31/2025 - PR Newswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
3/30/2025 - Globe Newswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
3/30/2025 - Globe Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
3/30/2025 - Globe Newswire
Investor Alert: Robbins LLP Informs Stockholders of the Actinium Pharmaceuticals, Inc. Class Action Lawsuit
3/28/2025 - PR Newswire
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)
3/28/2025 - Globe Newswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
3/28/2025 - Globe Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
9/25/2024 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
9/18/2024 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
9/10/2024 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
9/4/2024 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
8/27/2024 - PR Newswire
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
8/20/2024 - Globe Newswire
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
8/18/2024 - Business Wire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
8/18/2024 - PR Newswire
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
8/14/2024 - Globe Newswire
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
8/9/2024 - Business Wire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
8/9/2024 - PR Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$41.46M
EBIT (TTM)
-$42.12M
Net Income (TTM)
-$38.24M
Balance Sheet
Total Assets (Q)
$76.90M
Total Debt (Q)
$1.57M
Total Liabilities (Q)
$44.14M
Book Value Per Share (Q)
$1.05
Cash Flow
Cash from Operations (TTM)
-$33.07M
Cash from Investing (TTM)
-$11.00K
Cash from Financing (TTM)
$29.32M
Net Change in Cash (TTM)
-$3.76M
Filings
Filing Date
Monday, March 31, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
1.53
7-Day Total Return
-12.03%
30-Day Total Return
13.01%
60-Day Total Return
-2.80%
90-Day Total Return
0.00%
Year to Date Total Return
10.32%
1-Year Total Return
-84.28%
2-Year Total Return
-84.89%
3-Year Total Return
-73.77%
5-Year Total Return
-75.46%
52-week Low
Mar 04, 2025 - $1.03
52-week High
May 14, 2024 - $10.24
Valuation
Market Cap
$47.42M - Nano Cap
Enterprise Value
-$23.91M
Price/Sales (TTM)
--
Price/Book (Q)
1.45
Dividends and Shares
Shares Outstanding
31.20M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.actiniumpharma.com
Phone Number
646 677 3870
Address
100 Park Avenue
New York, NY 10017
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its... more
AMEX 04/03/2025 4:00PM Eastern Quotes delayed
Weiss Ratings